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ABSTRACT
Increasing data indicate that reduction of virus fitness may be beneficial for the host in persistent human
infections caused by RNA viruses, and that virus fitness can be targeted in clinical practice. Analysis of
virus fitness determinants in rapidly evolving RNA viruses has revealed that virus extinction may be
obtained in vitro by forcing virus populations through a lethal mutagenesis process, thus abolishing
virus replication by violation of the error threshold. It will be important in the future to evaluate the use
of novel compounds designed specifically to modulate virus fitness in vivo, and to optimise diagnostic
virology methods to enable a reliable large-scale evaluation of this approach.
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In the last two decades, the scientific community
has addressed the pathogenic potential of persis-
tent viruses and has obtained a better under-
standing of the mechanisms of virus replication at
the molecular level and the dynamic features of
virus–host relationships. This important work has
driven the rapid development of specific inhibi-
tors of virus replication, many of which are
currently being used with positive results for the
treatment of important virus infections in
humans. In addition, it has been possible to
formulate novel therapeutic strategies that modify
the equilibrium between persistent viruses and
their hosts, which are normally unable to clear the
pathogen. This is particularly important for infec-
tions caused by certain RNA viruses that have
shown unusual dynamic features of intra-host
evolution.
RNA viruses show mutation rates (10)3–10)5
base substitutions ⁄nucleotide copied) that are
several orders of magnitude greater than those
observed during replication of DNA viruses [1,2].
Far from being victims of this error-prone repli-
cation process, some RNA viruses, including
human immunodeficiency virus type 1 (HIV-1)
and hepatitis C virus, infect their hosts as
a population of closely related, non-identical
genomes (virus quasispecies) [3]. Each virus
quasispecies is dominated by one fit genome
(master sequence) that competes with a spectrum
of mutants, whose proportions depend on their
relative fitness in the environment [4]. Thus, virus
fitness (the replicative adaptation of a virus to its
environment) is a relative parameter with genetic
and non-genetic determinants, including the virus
replication capacity and an array of environ-
mental parameters. Among the environmental
parameters that act as a selective pressure,
susceptibility to antiviral compounds has great
clinical importance [5]. These findings have led to
an understanding of some of the fundamental
features of intra-host virus evolution, and have
stimulated a growing number of studies investi-
gating fitness changes among virus populations
in vivo [6,7]. Notably, these data have also
provided a theoretical basis for new antiviral
strategies addressing virus fitness [8].
A general consensus concerning the laboratory
methods to be used for analysing virus fitness is
required if this parameter is to be used for
monitoring patients with virus infections [9]. As
the ecosystem is a crucial determinant of in-vivo
virus fitness, studies performed in vitro have
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major limitations for modelling the environment
adequately [8–10]. As a consequence, contradic-
tory results have been obtained, depending on the
precise assay method used in different studies.
However, virus fitness can currently be evaluated
for: (i) a specific virus genomic region, after
cloning this region into a standard virus backbone
(a molecular clone); (ii) a specific virus isolate
(a biological clone); and (iii) a virus population
present in biological samples from an infected
patient. The major advantage of using molecular
clones is that the fitness changes can be linked
directly to sequence modifications in the cloned
virus region. The major advantage of using a
virus isolate is that the virus regions are present
in their normal context, thus including all of the
potential compensatory mutations (i.e., secondary
mutations that compensate for the defect intro-
duced by resistance mutations). Several ex-vivo
strategies have been proposed to evaluate the
fitness of single virus variants. These strategies
include: analysis of the replication capacity of
recombinant viruses over a single replication
cycle (either by limiting the time of the culture,
or by using potent inhibitors that block a second
round of infection); analysis of the replication
capacity, as measured by testing the amount of
virus produced over time; and competition exper-
iments (in which two virus strains are used in a
mixed infection after precise quantitation). Only
competitive methods seem to be capable of
detecting small differences in virus replication
capacity [8,9]; for this reason, they are currently
preferable to non-competitive techniques for eval-
uating the fitness of individual virus variants.
A large number of studies of HIV-1 patients
receiving anti-retroviral therapy (ART) have doc-
umented that drug-resistant virus strains bearing
specific resistance mutations (selected during
therapy) are rapidly replaced by wild-type
HIV-1 when treatment is interrupted [11]. It has
been demonstrated that most drug-resistant virus
strains selected during treatment, although capa-
ble of replicating efficiently in the presence of
drugs, show reduced virus fitness in the absence
of antiviral agents as compared to wild-type
clones [12]. Overall, the data suggest that,
although selection of resistant mutants is fre-
quent, both in vitro and in vivo, under the strong
selective pressure of antiviral compounds, rapidly
evolving RNA viruses normally pay a price in
terms of replication capacity for their survival.
The data also suggest the possible use of strate-
gies to modulate virus fitness in the presence of
drugs through resistance generation. A recent
clinical study [13] attempted to answer the ques-
tion of whether intentional reduction of virus
fitness is beneficial for the infected host. Variants
bearing the mutation M184V in the HIV-1 reverse
transcriptase gene are selected frequently during
ART treatment that includes lamivudine. This
mutation is associated with alterations in various
reverse transcriptase functions, leading to a drop
in HIV-1 replication capacity. In the prospective
clinical study, two groups of HIV-1 patients who
were failing under ART regimens and harbouring
a lamivudine-resistant virus were evaluated; a
first group of patients underwent treatment inter-
ruption, and a second group received lamivudine
monotherapy. A recovery in virus fitness was
observed at 48 weeks in the patients undergoing
treatment interruption, but not in the patients
who received lamivudine monotherapy. Interest-
ingly, loss of CD4+ T-cells was significantly higher
in the treatment interruption group than in the
lamivudine monotherapy group. These data indi-
cate that continued administration of lamivudine
to patients harbouring a lamivudine-resistant, less
fit virus resulted in a better immunological and
clinical outcome than complete therapy interrup-
tion.
Finally, novel antiviral strategies have been
proposed that do not target virus replication (the
principle that currently supports the use of ART
for HIV-1 infection), but aim to generate an ‘error
catastrophe’ in the virus population, with conse-
quent total loss of virus infectivity [14]. An initial
in-vitro demonstration of this concept was
obtained using poliovirus and vescicular stoma-
titis virus [15]; more recently, pro-mutagenic
nucleoside analogues have been used to abolish
in-vitro HIV-1 replication [16]. These studies
strongly suggest that a mutagen-dependent
reduction in virus replication capacity could be
an interesting alternative approach to virus inhi-
bition strategies.
In summary, a growing body of data indicate
that reduction of virus fitness may be beneficial
for the host in a large proportion of persistent
human infections by RNA viruses, and that
antiviral strategies targeting virus fitness can be
used in clinical practice. Specific analysis of the
determinants of virus fitness in highly evolving
RNA viruses has revealed that virus extinction
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may be obtained in vitro by forcing the virus
population through a lethal mutagenesis process,
thus abolishing virus replication by violation of
the error threshold. It will be of great interest in
the near future to evaluate the results of thera-
peutic strategies using novel compounds specif-
ically designed to modulate virus fitness in vivo.
In parallel, clinical virology laboratories should
optimise current diagnostic methods to allow a
reliable evaluation of this important determinant
of the pathogenic potential of viruses.
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